Search

Soliton’s (SOLY) Buy Rating Reiterated at Maxim Group

Soliton (NASDAQ:SOLY)‘s stock had its “buy” rating reissued by Maxim Group in a research note issued on Thursday, AnalystRatings.com reports. They presently have a $22.00 price objective on the stock. Maxim Group’s price objective would suggest a potential upside of 188.34% from the stock’s current price.


A number of other analysts also recently weighed in on SOLY. Zacks Investment Research downgraded shares of Soliton from a “buy” rating to a “hold” rating in a research report on Tuesday, May 26th. ValuEngine raised shares of Soliton from a “hold” rating to a “buy” rating in a research report on Thursday, April 2nd. Finally, Roth Capital lifted their price target on Soliton from $14.00 to $16.00 in a research note on Tuesday, June 16th.


SOLY stock traded down $0.04 during trading on Thursday, reaching $7.63. The stock had a trading volume of 18,846 shares, compared to its average volume of 465,058. The firm has a fifty day moving average price of $10.77 and a 200 day moving average price of $10.63. The company has a market capitalization of $132.05 million, a P/E ratio of -7.60 and a beta of 0.19. Soliton has a 1-year low of $6.64 and a 1-year high of $21.97.


Soliton (NASDAQ:SOLY) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.06. On average, research analysts expect that Soliton will post -0.75 EPS for the current fiscal year.


In other Soliton news, major shareholder Remeditex Ventures Llc acquired 120,481 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was acquired at an average price of $8.30 per share, with a total value of $999,992.30. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 11.30% of the company’s stock.


A number of large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in Soliton by 24.8% in the first quarter. JPMorgan Chase & Co. now owns 8,896 shares of the company’s stock worth $72,000 after buying an additional 1,765 shares during the period. UBS Group AG lifted its position in Soliton by 38.5% in the 4th quarter. UBS Group AG now owns 6,841 shares of the company’s stock valued at $75,000 after purchasing an additional 1,903 shares during the last quarter. Matisse Capital acquired a new position in Soliton during the 1st quarter valued at about $108,000. Bank of New York Mellon Corp boosted its stake in Soliton by 19.0% during the 1st quarter. Bank of New York Mellon Corp now owns 17,560 shares of the company’s stock valued at $142,000 after purchasing an additional 2,804 shares during the period. Finally, Oxford Asset Management LLP acquired a new stake in shares of Soliton in the fourth quarter valued at approximately $209,000. Institutional investors and hedge funds own 11.81% of the company’s stock.


Soliton Company Profile

Soliton, Inc, an early stage medical device company, focuses on developing and commercializing products using a proprietary rapid acoustic pulse technology platform. It offers a device for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.


Source: https://weekherald.com/2020/07/02/solitons-soly-buy-rating-reiterated-at-maxim-group.html

Recent Posts

See All

Logiq Launches Exclusive Mobile Payment Services

for Required Driver License Testing Across Indonesia NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Logiq, Inc. (NEO: LGIQ) (OTCQX: LGIQ), a global provider of award-winning e-commerce and fintech solut

Quantum Computing Inc. Announces QUBT University

Program Helps Students Learn How to Solve Complex Optimization Problems with Access to Qatalyst and Quantum Educational Resources LEESBURG, Va., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Quantum Computing Inc